Imperial College NHS Trust CML ( I-CML) database
Research type
Research Study
Full title
Analysis of a Large Single Centre Chronic Myeloid Leukaemia database at Imperial College NHS Trust (Hammersmith Hospital Site)
IRAS ID
336937
Contact name
Dragana Milojkovic
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
4 years, 11 months, 5 days
Research summary
Chronic Myeloid Leukemia (CML) is one of the family of myeloproliferative malignancies, where a significant excess of cells is produced in the bone marrow. The hallmark of CML is the identification of an abnormal chromosome, the Philadelphia chromosome, which results from an exchange of genetic material between chromosome no 9 and chromosome no 22. This switch of genetic material creates a new abnormal protein, which results in leukemic cells surviving longer and expanding, replacing the normal blood cells . CML starts of as a more indolent chronic condition ( known as chronic phase) , treated as an out-patient with tablet therapy, but can transform if not treated adequately to a more aggressive form that resembles an acute leukaemia needing admission and more intensive chemotherapy type treatment ( known as advanced phase) .
Treatment of CML has undergone a significant change since the development of imatinib, the first targeted treatment against CML, which has led to marked improvements in the prognosis of chronic phase CML (CP-CML) with survival rates of >90% at 10 years, with the majority of patients now experiencing near normal life expectancy. Six TKIs have now been introduced in the management of CML, however unrestricted real world (RW) responses remain important to determine the true outcome of treatment. Despite marked medical advances, there remain several unanswered research questions.
We plan to use both retrospective and prospective data collected from the Hammersmith CML Database to answer critical unanswered questions pertaining to CML.
Hammersmith Hospital is a CML centre of excellence with sizeable patient population, therefore data collection of these patients in the Hammersmith Hospital CML database would help provide important insights into various aspects of CML, including demographics, incidence, response assessments, survival and outcome data.
REC name
Yorkshire & The Humber - Sheffield Research Ethics Committee
REC reference
24/YH/0245
Date of REC Opinion
4 Dec 2024
REC opinion
Further Information Favourable Opinion